Literature DB >> 1539745

Leishmania chagasi antigens recognized in cured visceral leishmaniasis and asymptomatic infection.

A C White1, M Castes, L Garcia, D Trujillo, L Zambrano.   

Abstract

Active visceral leishmaniasis is associated with antigen-specific immuno-suppression. However, cured patients develop a cellular immune response associated with resistance to reinfection. Recent studies have identified patients with asymptomatic or subclinical infections, which are also accompanied by an immune response. In order to identify subjects immune to Leishmania chagasi, we performed a skin-test survey in an endemic area in eastern Venezuela. The delayed-type hypersensitivity (DTH) response was assessed in patients cured of visceral leishmaniasis, as well as in their relatives and neighbors. Of the latter, 36 (34.2%) of 105 were positive and 26 (24.7%) of 105 gave intermediate responses. The DTH reaction correlated with age. The antigens recognized by a subgroup of cured patients, those with positive skin-test results, and controls (skin-test negative) were assessed by Western blotting with sera, and T cell immunoblotting with peripheral blood mononuclear cells. No consistent differences between the groups were noted in Western blots with L. chagasi antigens. T cell blots were performed on five patients from each group. For the cured patients and skin-test positive contacts, a significant proliferative response to fraction 12 (less than 20.5 kDa) was noted in four of five patients in each group. Cells from three of five cured patients and two of five skin-test-positive patients proliferated in response to fraction 4 (73-115 kDa). The response to other fractions was variable, with only a minority of patients responding to any one fraction. These data suggest that the antigens recognized by patients with evidence of immunity to L. chagasi are quite variable.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1539745     DOI: 10.4269/ajtmh.1992.46.123

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

1.  Identification of Leishmania donovani antigens stimulating cellular immune responses in exposed immune individuals.

Authors:  P Tripathi; S Ray; S Sunder; A Dube; S Naik
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

2.  Leishmania infantum chagasi in northeastern Brazil: asymptomatic infection at the urban perimeter.

Authors:  Iraci D Lima; Jose W Queiroz; Henio G Lacerda; Paula V S Queiroz; Nubia N Pontes; James D A Barbosa; Daniella R Martins; Jason L Weirather; Richard D Pearson; Mary E Wilson; Selma M B Jeronimo
Journal:  Am J Trop Med Hyg       Date:  2012-01       Impact factor: 2.345

Review 3.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

4.  Immunologic indicators of clinical progression during canine Leishmania infantum infection.

Authors:  Paola M Boggiatto; Amanda E Ramer-Tait; Kyle Metz; Erin E Kramer; Katherine Gibson-Corley; Kathleen Mullin; Jesse M Hostetter; Jack M Gallup; Douglas E Jones; Christine A Petersen
Journal:  Clin Vaccine Immunol       Date:  2009-12-23

5.  Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters.

Authors:  Shraddha Kumari; Pragya Misra; Rati Tandon; Mukesh Samant; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2012-01-26       Impact factor: 3.240

6.  Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis.

Authors:  Susanne Nylén; Radheshyam Maurya; Liv Eidsmo; Krishna Das Manandhar; Shyam Sundar; David Sacks
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

7.  Nucleosomal histone proteins of L. donovani: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against Leishmania challenge in hamsters.

Authors:  Rajendra K Baharia; Rati Tandon; Amogh A Sahasrabuddhe; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

8.  Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.

Authors:  Rajendra K Baharia; Rati Tandon; Tanuj Sharma; Manish K Suthar; Sanchita Das; Mohammad Imran Siddiqi; Jitendra Kumar Saxena; Shaym Sundar; Shyam Sunder; Anuradha Dube
Journal:  PLoS Negl Trop Dis       Date:  2015-03-06

9.  Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin g fc N-glycosylation.

Authors:  Luiz Gustavo Gardinassi; Viktoria Dotz; Agnes Hipgrave Ederveen; Roque Pacheco de Almeida; Carlos Henrique Nery Costa; Dorcas Lamounier Costa; Amélia Ribeiro de Jesus; Oleg A Mayboroda; Gustavo Rocha Garcia; Manfred Wuhrer; Isabel Kinney Ferreira de Miranda Santos
Journal:  MBio       Date:  2014-12-02       Impact factor: 7.867

10.  Immunobiology of visceral leishmaniasis.

Authors:  Rajiv Kumar; Susanne Nylén
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.